Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 851,418
  • Shares Outstanding, K 47,170
  • Annual Sales, $ 230,060 K
  • Annual Income, $ 18,490 K
  • 36-Month Beta 1.45
  • Price/Sales 3.26
  • Price/Cash Flow 7.49
  • Price/Book 21.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.50 +9.39%
on 12/18/17
18.75 -3.73%
on 01/08/18
+1.05 (+6.18%)
since 12/15/17
3-Month
9.45 +91.01%
on 11/02/17
18.75 -3.73%
on 01/08/18
+8.05 (+80.50%)
since 10/16/17
52-Week
9.30 +94.09%
on 04/18/17
18.75 -3.73%
on 01/08/18
+5.55 (+44.40%)
since 01/13/17

Most Recent Stories

More News
Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?

Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.

ENDP : 8.01 (+0.75%)
SCMP : 18.05 (unch)
EXEL : 29.65 (-2.40%)
MNK : 23.13 (-1.57%)
Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

XOMA : 31.56 (-6.38%)
ARDM : 2.06 (-8.85%)
SCMP : 18.05 (unch)
EXEL : 29.65 (-2.40%)
Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

We look at the factors that drive the share price of Perrigo to a 52-week high.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
EXEL : 29.65 (-2.40%)
PRGO : 90.86 (-1.02%)
Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse

Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.

ENDP : 8.01 (+0.75%)
SCMP : 18.05 (unch)
EXEL : 29.65 (-2.40%)
MNK : 23.13 (-1.57%)
Why is Novo Nordisk Stock Up More Than 50% in Past Year?

We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
NVO : 55.31 (+0.49%)
EXEL : 29.65 (-2.40%)
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
ADMS : 35.74 (+0.45%)
EXEL : 29.65 (-2.40%)
Acorda's Shares Down on Disappointing Ampyra View for 2018

Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
EXEL : 29.65 (-2.40%)
ACOR : 25.05 (-3.09%)
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
NVO : 55.31 (+0.49%)
EXEL : 29.65 (-2.40%)
Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter

Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to...

SCMP : 18.05 (unch)
MDCO : 25.67 (-6.69%)
BAX : 67.67 (-0.98%)
MNK : 23.13 (-1.57%)
Emergent Starts Phase II Study on Anti-influenza Candidate

Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.

XOMA : 31.56 (-6.38%)
SCMP : 18.05 (unch)
EBS : 48.82 (+2.69%)
EXEL : 29.65 (-2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical...

See More

Key Turning Points

2nd Resistance Point 18.16
1st Resistance Point 18.11
Last Price 18.05
1st Support Level 18.00
2nd Support Level 17.94

See More

52-Week High 18.75
Last Price 18.05
Fibonacci 61.8% 15.14
Fibonacci 50% 14.02
Fibonacci 38.2% 12.91
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.